People · Operator
Named in public records as an officer, director or promoter · active 2008–2019 · Other, Other Technology, Other Health Care, Other Energy, Agriculture, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CHC Group LLC | — | Other | Growth/Late | $464.1M | $8.2B | 2017 |
| Zift Solutions Inc. | — | Other Technology | Series A | $23.2M | $396.3M | 2013 |
| Nugen Technologies Inc | — | Other Health Care | Series A | $11.2M | $124.7M | 2010 |
| VERATECT Corp | — | Other | Series A | $7.6M | $63.7M | 2009 |
| Acumentrics Holding Corp | — | Other Energy | Seed | $3.1M | $26.0M | 2009 |
| Zea Biosciences Corp | — | Agriculture | Seed | $2.7M | $3.6M | 2015 |
| Designmedix Inc | — | Pharmaceuticals | Seed | $2.4M | $24.8M | 2008 |
| Azima Holdings Inc | — | Other Technology | Seed | $2.2M | $21.5M | 2010 |
| SmartBIM LLC | — | Other Technology | Seed | $1.3M | $43.5M | 2010 |
| Northwest Physicians Network of Washington LLC | — | Hospitals and Physicians | Pre-Seed | $158K | $4.5M | 2012 |
James Wilson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Wilson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Rosenfield | 2 | 3 |
| David Miller | 1 | 29 |
| JEFF BIRD | 1 | 7 |
| Matthew White | 1 | 5 |
| Lee Huntsman | 1 | 5 |
| John Carleton | 1 | 5 |
| Andy Wilson | 1 | 4 |
| Jennifer Smith | 1 | 4 |
| Jason Caplain | 1 | 3 |
| Lynnor B. Stevenson | 1 | 3 |
| Andrew Brooks | 1 | 3 |
| Dennis Weston | 1 | 3 |
| Arol Wolford | 1 | 3 |
| Jonathan Hakim | 1 | 3 |
| Gary Simon | 1 | 2 |
| Joseph Velk | 1 | 2 |
| Elizabeth Hutt | 1 | 2 |
| John Humphrey | 1 | 2 |
| Nicole Wicker | 1 | 2 |
| Robert S Hart | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.